论文部分内容阅读
许多研究认为,急性髓细胞白血病(AML)原始细胞抗原CD34表达不利于完全缓解(CR)的预后因素。作者观察了1990～1992年诊断的80例成人AML中CD34表达与某些临床特征和结局的关系,探讨CD34表达在评价预后中的作用。 80例成人AML按FAB标准确定亚型,其中M0型指常规形态学和细胞化学方法不能检测出髓系标记,但表达髓系相关抗原CD13或CD33。亚型分布:M0 3例、M1 20例、M2 23例,M4 22例、M5 7
Many studies suggest that the expression of CD34 antigen in acute myeloid leukemia (AML) is not conducive to the prognostic factors of complete remission (CR). The authors looked at the relationship between CD34 expression in 80 AML cases diagnosed between 1990 and 1992 with some clinical features and outcomes and the role of CD34 expression in the evaluation of prognosis. Eighty adult AMLs were subtyped according to the FAB criteria. M0 type means that myeloid markers can not be detected by conventional morphological and cytochemical methods but express myeloid-associated antigens CD13 or CD33. Subtype distribution: M0 3 cases, M1 20 cases, M2 23 cases, M4 22 cases, M5 7